IL265761B2 - Oral terlipressin compositions for use in treatment of ascites - Google Patents
Oral terlipressin compositions for use in treatment of ascitesInfo
- Publication number
- IL265761B2 IL265761B2 IL265761A IL26576119A IL265761B2 IL 265761 B2 IL265761 B2 IL 265761B2 IL 265761 A IL265761 A IL 265761A IL 26576119 A IL26576119 A IL 26576119A IL 265761 B2 IL265761 B2 IL 265761B2
- Authority
- IL
- Israel
- Prior art keywords
- terlipressin
- composition
- administered
- daily
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410971P | 2016-10-21 | 2016-10-21 | |
| US201762472291P | 2017-03-16 | 2017-03-16 | |
| PCT/US2017/057601 WO2018075897A1 (en) | 2016-10-21 | 2017-10-20 | Terlipressin compositions and their methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL265761A IL265761A (en) | 2019-06-30 |
| IL265761B1 IL265761B1 (en) | 2024-07-01 |
| IL265761B2 true IL265761B2 (en) | 2024-11-01 |
Family
ID=62019439
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL265761A IL265761B2 (en) | 2016-10-21 | 2017-10-20 | Oral terlipressin compositions for use in treatment of ascites |
| IL313083A IL313083A (en) | 2016-10-21 | 2017-10-20 | Tralipressin compounds and methods of using them |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313083A IL313083A (en) | 2016-10-21 | 2017-10-20 | Tralipressin compounds and methods of using them |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10993984B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP4516803A3 (cg-RX-API-DMAC10.html) |
| JP (3) | JP2020500164A (cg-RX-API-DMAC10.html) |
| AU (2) | AU2017345720B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3037581A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES3023754T3 (cg-RX-API-DMAC10.html) |
| IL (2) | IL265761B2 (cg-RX-API-DMAC10.html) |
| MA (1) | MA46586A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018075897A1 (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA201901912B (cg-RX-API-DMAC10.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2678833C2 (ru) | 2008-09-17 | 2019-02-04 | Киазма Инк. | Фармацевтические композиции и соответствующие способы доставки |
| SI3253401T1 (sl) | 2015-02-03 | 2025-07-31 | Amryt Endo, Inc. | Zdravljenje akromegalije z oralnim oktreotidom |
| CN109223720B (zh) * | 2018-09-12 | 2020-11-27 | 南京康舟医药科技有限公司 | 注射用醋酸特利加压素冻干粉针剂的制备方法 |
| US20230399360A1 (en) * | 2019-12-20 | 2023-12-14 | Northwestern University | Terlipressin-octadecanedioic acid conjugate for vasoconstrictive therapy |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
| CN114306250B (zh) * | 2021-11-26 | 2023-07-14 | 苏州天马医药集团天吉生物制药有限公司 | 一种醋酸特利加压素制剂及其制备方法 |
| CA3238277A1 (en) * | 2022-01-13 | 2023-07-20 | David Caron | Oral dosage forms |
| US20240156895A1 (en) * | 2022-10-28 | 2024-05-16 | Mallinckrodt Pharmaceuticals Ireland Limited | Compositions for improving kidney function in patients with hepatorenal syndrome |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110257095A1 (en) * | 2008-09-17 | 2011-10-20 | Paul Salama | Pharmaceutical compositions and related methods of delivery |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH455823A (de) | 1964-08-01 | 1968-05-15 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung von Peptiden |
| EP1188443A1 (en) | 2000-09-15 | 2002-03-20 | Ferring BV | Improved protocol for paracentesis |
| JO2937B1 (en) | 2004-08-11 | 2016-03-15 | فيرينغ.بي.في | Tight muscles of the peptide vascular tensioner receptor |
| US8883965B2 (en) | 2006-02-10 | 2014-11-11 | Ferring B.V. | Compounds |
| GB2438834A (en) | 2006-06-08 | 2007-12-12 | Optinose As | Intranasal protein administration |
| US7960336B2 (en) * | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| AU2015201581B2 (en) * | 2008-09-17 | 2017-03-09 | Amryt Endo, Inc. | Pharmaceutical Compositions and Related Methods of Delivery |
| WO2011116139A2 (en) * | 2010-03-16 | 2011-09-22 | Chiasma Inc. | Improved pharmaceutical compositions and methods of delivery |
| WO2014165607A2 (en) * | 2013-04-02 | 2014-10-09 | Stealth Peptides International, Inc. | Aromatic-cationic peptide formulations, compositions and methods of use |
| JO3371B1 (ar) | 2013-07-26 | 2019-03-13 | Ferring Bv | ناهضات مستقبل فاسوبريسين 2 |
| AU2015335855A1 (en) * | 2014-10-24 | 2017-05-18 | Mallinckrodt Hospital Products IP Limited | Method of treating patients with hepatorenal syndrome type 1 |
| AU2016240068B9 (en) | 2015-03-30 | 2020-07-30 | Sunnybrook Research Institute | Method for treating cancer |
| JP2017014206A (ja) | 2015-06-30 | 2017-01-19 | ナノアンティバイオティクス，インコーポレイテッド | 腹水の治療 |
-
2017
- 2017-10-20 MA MA046586A patent/MA46586A/fr unknown
- 2017-10-20 EP EP25152377.5A patent/EP4516803A3/en active Pending
- 2017-10-20 AU AU2017345720A patent/AU2017345720B2/en active Active
- 2017-10-20 IL IL265761A patent/IL265761B2/en unknown
- 2017-10-20 IL IL313083A patent/IL313083A/en unknown
- 2017-10-20 US US16/343,232 patent/US10993984B2/en active Active
- 2017-10-20 EP EP17862085.2A patent/EP3528828B1/en active Active
- 2017-10-20 JP JP2019521093A patent/JP2020500164A/ja not_active Withdrawn
- 2017-10-20 ES ES17862085T patent/ES3023754T3/es active Active
- 2017-10-20 CA CA3037581A patent/CA3037581A1/en active Pending
- 2017-10-20 WO PCT/US2017/057601 patent/WO2018075897A1/en not_active Ceased
-
2019
- 2019-03-27 ZA ZA2019/01912A patent/ZA201901912B/en unknown
-
2021
- 2021-11-11 US US17/524,022 patent/US20220313773A1/en not_active Abandoned
-
2023
- 2023-06-30 JP JP2023108121A patent/JP2023120445A/ja not_active Withdrawn
- 2023-10-27 AU AU2023255036A patent/AU2023255036B2/en active Active
-
2024
- 2024-01-31 US US18/429,227 patent/US20250000933A1/en active Pending
- 2024-11-06 JP JP2024194379A patent/JP2025020319A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110257095A1 (en) * | 2008-09-17 | 2011-10-20 | Paul Salama | Pharmaceutical compositions and related methods of delivery |
| US20160158159A1 (en) * | 2008-09-17 | 2016-06-09 | Chiasma Inc. | Pharmaceutical compositions and related methods of delivery |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017345720B2 (en) | 2023-07-27 |
| IL265761B1 (en) | 2024-07-01 |
| JP2023120445A (ja) | 2023-08-29 |
| US10993984B2 (en) | 2021-05-04 |
| EP4516803A3 (en) | 2025-06-25 |
| AU2023255036B2 (en) | 2026-06-18 |
| EP3528828B1 (en) | 2025-01-29 |
| US20250000933A1 (en) | 2025-01-02 |
| JP2025020319A (ja) | 2025-02-12 |
| AU2023255036A1 (en) | 2023-11-16 |
| AU2017345720A1 (en) | 2019-04-11 |
| JP2020500164A (ja) | 2020-01-09 |
| NZ751717A (en) | 2025-05-02 |
| IL265761A (en) | 2019-06-30 |
| US20190240284A1 (en) | 2019-08-08 |
| ES3023754T3 (en) | 2025-06-03 |
| IL313083A (en) | 2024-07-01 |
| EP4516803A2 (en) | 2025-03-05 |
| MA46586A (fr) | 2019-08-28 |
| WO2018075897A1 (en) | 2018-04-26 |
| CA3037581A1 (en) | 2018-04-26 |
| EP3528828A1 (en) | 2019-08-28 |
| US20220313773A1 (en) | 2022-10-06 |
| ZA201901912B (en) | 2023-10-25 |
| EP3528828A4 (en) | 2020-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265761B1 (en) | Oral terlipressin compositions for use in treatment of ascites | |
| RU2470016C2 (ru) | Производное бипиразола | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| RU2010140682A (ru) | Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство | |
| JP2018513188A5 (cg-RX-API-DMAC10.html) | ||
| JP2023500032A5 (cg-RX-API-DMAC10.html) | ||
| US20240382512A1 (en) | Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof | |
| JP2016505050A5 (cg-RX-API-DMAC10.html) | ||
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| BRPI0610592A2 (pt) | formulações e métodos para o tratamento da amiloidose | |
| WO2012020785A1 (ja) | 肝細胞がんの予防及び／又は治療のための医薬 | |
| KR20120138229A (ko) | 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료 | |
| HRP20240812T1 (hr) | Oblici doziranja i terapijska primjena l-4-klorokinurenina | |
| JP2022019937A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物 | |
| CO2025007025A2 (es) | Formulaciones orales compactables de ibutamoren | |
| FI105075B (fi) | Kombinaatioinjektiovalmisteen käyttö | |
| JP2019535830A5 (cg-RX-API-DMAC10.html) | ||
| CN101400255B (zh) | 用于治疗细菌、病毒、真菌疾病、炎症以及疼痛的组合物 | |
| US20250387371A1 (en) | Compositions and formulation methods for sustained local release of antifibrotics | |
| CN106535913A (zh) | 神经活性肽的稳定组合物 | |
| US12168000B2 (en) | Methods of treating pain | |
| IT201800006455A1 (it) | Nuovo utilizzo degli inibitori della monoammino ossidasi B | |
| US10213444B2 (en) | Composition and method for treating bipolar disorder | |
| CN103371987B (zh) | 漆酚化合物在制备抑制肾脏组织纤维化的药物中的用途 | |
| CN111228247B (zh) | 一种用于治疗包虫病的含苯亚甲基丙酮药物及其制备方法 |